• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将公平性纳入经济评估:一种多属性公平状态方法。

Incorporating equity in economic evaluations: a multi-attribute equity state approach.

机构信息

School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

School of Public Health, University of Alberta, Edmonton, Canada.

出版信息

Eur J Health Econ. 2018 May;19(4):489-498. doi: 10.1007/s10198-017-0897-3. Epub 2017 Jun 1.

DOI:10.1007/s10198-017-0897-3
PMID:28573333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5913380/
Abstract

In publicly funded health care systems, decision makers must continually balance often conflicting priorities of efficiency and equity. Health economists have developed a set of highly sophisticated analytical methods for assessing efficiency, but less attention has been paid to formally incorporating equity considerations into analyses. As a result, where equity is considered is often informal, ad hoc and/or simplistic. This paper is a proposal for a mechanism for formally incorporating equity within the decision process. It begins with an overview of the current literature on equity weighting. It then considers the case of a single equity domain and illustrates how this is currently applied in practice by the UK's National Institute for Health and Care Excellence. It then proposes a more comprehensive method for considering the multi-attribute equity state, where a population exhibits more than one trait considered worthy of differential weighting. Finally, the paper proposes a mechanism by which this could be applied in practice, and concludes with a discussion of the challenges for applying multi-attribute equity weighting.

摘要

在公共资助的医疗保健系统中,决策者必须不断平衡效率和公平这两个常常相互冲突的优先事项。卫生经济学家已经开发出了一系列用于评估效率的高度复杂的分析方法,但对将公平因素正式纳入分析的关注较少。因此,在考虑公平性的地方,往往是非正式的、临时的和/或简单的。本文提出了一种在决策过程中正式纳入公平性的机制。它首先概述了当前关于公平权重的文献。然后考虑了单一公平领域的情况,并说明了英国国家卫生与保健卓越研究所目前如何在实践中应用这一情况。然后提出了一种更全面的方法来考虑多属性公平状态,即一个群体表现出一种以上值得差异化加权的特征。最后,本文提出了一种在实践中应用这种方法的机制,并讨论了应用多属性公平权重的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc1/5913380/0c395b40a7e8/10198_2017_897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc1/5913380/0c395b40a7e8/10198_2017_897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afc1/5913380/0c395b40a7e8/10198_2017_897_Fig1_HTML.jpg

相似文献

1
Incorporating equity in economic evaluations: a multi-attribute equity state approach.将公平性纳入经济评估:一种多属性公平状态方法。
Eur J Health Econ. 2018 May;19(4):489-498. doi: 10.1007/s10198-017-0897-3. Epub 2017 Jun 1.
2
Equity and efficiency preferences of health policy makers in China--a stated preference analysis.中国卫生政策制定者的公平与效率偏好——一项陈述性偏好分析
Health Policy Plan. 2015 Oct;30(8):1059-66. doi: 10.1093/heapol/czu123. Epub 2014 Dec 13.
3
Mapping the evidence on health equity considerations in economic evaluations of health interventions: a scoping review protocol.绘制健康干预经济评估中健康公平性考虑因素的证据图谱:系统评价方案。
Syst Rev. 2020 Jan 8;9(1):6. doi: 10.1186/s13643-019-1257-4.
4
Modifying NICE's Approach to Equity Weighting.修改 NICE 的公平加权方法。
Pharmacoeconomics. 2021 Feb;39(2):147-160. doi: 10.1007/s40273-020-00988-2. Epub 2021 Jan 31.
5
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.将公平性问题纳入成本效益分析中:系统文献回顾。
Pharmacoeconomics. 2022 Jan;40(1):45-64. doi: 10.1007/s40273-021-01094-7. Epub 2021 Oct 29.
6
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.权衡必须等待:将公平性问题纳入成本效益分析可能需要比预期更长的时间。
Pharmacoeconomics. 2009;27(12):983-9. doi: 10.2165/11314100-000000000-00000.
7
Incorporating equity-efficiency interactions in cost-effectiveness analysis-three approaches applied to breast cancer control.将公平-效率相互作用纳入成本效益分析——三种方法在乳腺癌控制中的应用。
Value Health. 2010 Aug;13(5):573-9. doi: 10.1111/j.1524-4733.2010.00718.x. Epub 2010 Mar 31.
8
Efficiency and equity considerations in the preferences of health policy-makers in Israel.以色列卫生政策制定者偏好中的效率与公平考量。
Isr J Health Policy Res. 2017 Apr 1;6:18. doi: 10.1186/s13584-017-0142-7. eCollection 2017.
9
An equity framework for health technology assessments.卫生技术评估的股权框架。
Med Decis Making. 2012 May-Jun;32(3):428-41. doi: 10.1177/0272989X11426484. Epub 2011 Nov 7.
10
Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.三个欧洲国家报销决策中决策者对公平/效率属性偏好的比较分析。
Eur J Health Econ. 2016 Sep;17(7):791-9. doi: 10.1007/s10198-015-0721-x. Epub 2015 Aug 22.

引用本文的文献

1
Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity.基因组医学中的分布成本效益分析:解决健康公平问题的考量因素
Value Health. 2025 May 6. doi: 10.1016/j.jval.2025.04.2162.
2
"Blanket rules just don't work": Qualitative exploration of the relative value of child and adult quality-adjusted life year (QALY) gains for health technology assessment.“一刀切的规则行不通”:对儿童和成人质量调整生命年(QALY)增益在卫生技术评估中的相对价值的定性探索。
Int J Technol Assess Health Care. 2025 Mar 28;41(1):e23. doi: 10.1017/S0266462325000194.
3
The economic evaluation of a housing maintenance project to improve the health of Aboriginal housing tenants in NSW: A scoping literature review and protocol for an economic analysis.

本文引用的文献

1
Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care.复杂评估:将复杂干预框架中的理念应用于临终关怀新措施的评估
Pharmacoeconomics. 2016 May;34(5):499-508. doi: 10.1007/s40273-015-0365-9.
2
CONSIDERING EQUITY IN HEALTH TECHNOLOGY ASSESSMENT: AN EXPLORATORY ANALYSIS OF AGENCY PRACTICES.考量卫生技术评估中的公平性:对机构实践的探索性分析
Int J Technol Assess Health Care. 2015 Jan;31(5):314-23. doi: 10.1017/S0266462315000549. Epub 2015 Dec 29.
3
Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
新南威尔士州一项旨在改善原住民住房租户健康状况的住房维护项目的经济评估:范围界定文献综述与经济分析方案
Heliyon. 2024 Jul 9;10(14):e34282. doi: 10.1016/j.heliyon.2024.e34282. eCollection 2024 Jul 30.
4
A QALY is [still] a QALY is [still] a QALY? : Evaluating proportional shortfall as the answer to the problem of equity in healthcare allocations.一个 QALY 仍然是一个 QALY 仍然是一个 QALY?:评估比例差距作为解决医疗保健分配公平性问题的答案。
BMC Med Ethics. 2024 Mar 23;25(1):35. doi: 10.1186/s12910-024-01036-w.
5
Considering equity in priority setting using transmission models: Recommendations and data needs.考虑使用传播模型确定优先顺序的公平性:建议和数据需求。
Epidemics. 2022 Dec;41:100648. doi: 10.1016/j.epidem.2022.100648. Epub 2022 Nov 1.
6
Costs and cost-effectiveness of HIV counselling and testing modalities in Southern Mozambique.莫桑比克南部地区艾滋病病毒咨询与检测方式的成本及成本效益
Cost Eff Resour Alloc. 2022 Sep 6;20(1):49. doi: 10.1186/s12962-022-00378-9.
7
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.将公平性问题纳入成本效益分析中:系统文献回顾。
Pharmacoeconomics. 2022 Jan;40(1):45-64. doi: 10.1007/s40273-021-01094-7. Epub 2021 Oct 29.
8
Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.在质量调整生命年背景下对“健康之外的益处”进行概念化:一项批判性解释性综述
Pharmacoeconomics. 2021 Dec;39(12):1383-1395. doi: 10.1007/s40273-021-01074-x. Epub 2021 Aug 23.
9
Why it's Time to Abandon the ICER.为何是时候摒弃成本效果分析(ICER)了。
Pharmacoeconomics. 2020 Aug;38(8):781-784. doi: 10.1007/s40273-020-00915-5.
10
Methods to promote equity in health resource allocation in low- and middle-income countries: an overview.促进中低收入国家卫生资源配置公平性的方法:概述。
Global Health. 2020 Jan 13;16(1):6. doi: 10.1186/s12992-019-0537-z.
获取社会对疾病负担和生命末期质量调整生命年(QALY)加权的偏好。
Med Decis Making. 2016 Feb;36(2):210-22. doi: 10.1177/0272989X15619389. Epub 2015 Dec 15.
4
Attributes and weights in health care priority setting: A systematic review of what counts and to what extent.医疗保健优先事项设定中的属性与权重:对重要因素及其影响程度的系统评价
Soc Sci Med. 2015 Dec;146:41-52. doi: 10.1016/j.socscimed.2015.10.005. Epub 2015 Oct 9.
5
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.英国国家卫生与临床优化研究所成本效益阈值的估计方法。
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
6
Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework.罕见病药物基于价值的报销决策:一项范围综述与决策框架
Pharmacoeconomics. 2015 Mar;33(3):255-69. doi: 10.1007/s40273-014-0235-x.
7
Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.重新评估英国普遍接种脑膜炎疫苗(Bexsero)的成本效益:建模研究。
BMJ. 2014 Oct 9;349:g5725. doi: 10.1136/bmj.g5725.
8
Where is the evidence for the existence of the Cancer Drugs Fund?癌症药物基金存在的证据在哪里?
BMJ. 2014 Sep 30;349:g5901. doi: 10.1136/bmj.g5901.
9
Some inconsistencies in NICE's consideration of social values.英国国家卫生与临床优化研究所(NICE)在社会价值观考量方面存在一些不一致之处。
Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.
10
Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment.社会在医疗保健资源分配中对分配正义的偏好:一项潜在类别离散选择实验。
Med Decis Making. 2015 Jan;35(1):94-105. doi: 10.1177/0272989X14547915. Epub 2014 Aug 21.